Search Results - "Leip, E"

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy by Campone, M., Bondarenko, I., Brincat, S., Hotko, Y., Munster, P.N., Chmielowska, E., Fumoleau, P., Ward, R., Bardy-Bouxin, N., Leip, E., Turnbull, K., Zacharchuk, C., Epstein, R.J.

“…This phase II study evaluated single-agent bosutinib in pretreated patients with locally advanced or metastatic breast cancer. Patients received oral bosutinib…”
Get full text

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study by Isakoff, S J, Wang, D, Campone, M, Calles, A, Leip, E, Turnbull, K, Bardy-Bouxin, N, Duvillié, L, Calvo, E

“…Background: This phase 1 study evaluated the maximum tolerated dose (MTD), safety, and efficacy of bosutinib (competitive Src/Abl tyrosine kinase inhibitor)…”
Get full text

EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3 by N Raje, X Leleu, A Lesokhin, M Mohty, A Nooka, E Leip, U Conte, A Viqueira, V Blunk, S Manier

“…Introduction/Objectives: Multiple myeloma is a disease of elderly and frail people, who are often predominantly ineligible for intensive therapies. The…”
Get full text

Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: Subgroup analysis from the BELA trial by Malhotra, H., Maru, A., Khattry, N., Ramanan, M.V., Leip, E., Crescenzo, R.J., Gambacorti-Passerini, C., Cortes, J.E.

Get full text

Treatment of Unruptured Intracranial Aneurysms: A Nationwide Assessment of Effectiveness by Higashida, R.T, Lahue, B.J, Torbey, M.T, Hopkins, L.N, Leip, E, Hanley, D.F

“…With advances in neuroimaging, unruptured cerebral aneurysms are being diagnosed more frequently. Until 1995, surgical clipping of the aneurysm was the only…”
Get full text

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES by A Nooka, A Lesokhin, M Mohty, R Niesvizky, C Maisel, B Arnulf, S Larson, A Varshavsky-Yanovsky, X Leleu, L Karlin, D Vesole, N Bahlis, CF Larrea, N Raje, E Leip, U Conte, M Elmeliegy, A Viqueira, V Blunk, S Manier

“…Introduction/Objectives: To evaluate the efficacy and safety of elranatamab in a pooled analysis of patients (pts) enrolled in MagnetisMM trials with relapsed…”
Get full text

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY by M Mohty, M Tomasson, B Arnulf, N Bahlis, M Prince, R Niesvizky, P Rodrgue-Otero, J Martine-Lopez, G Koehne, Y Jethava, A Gabayan, D Stevens, A Nooka, N Raje, S Iida, E Leip, U Conte, A Czibere, A Viqueira, V Blunk, A Lesokhin

“…Introduction/Objectives: To report the findings of extended follow-up and biweekly administration of elranatamab monotherapy in patients (pts) with…”
Get full text

P719: EFFICACY AND SAFETY OF BOSUTINIB IN LATER‐LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB‐ANALYSIS FROM THE PHASE 4 BYOND TRIAL by Gambacorti‐Passerini, C., Brümmendorf, T. H., Ernst, T., Leip, E., Purcell, S., Viqueira, A., Giles, F. J., Rosti, G., Hochhaus, A.

Get full text

P717: BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL by Cortes, J. E., Milojkovic, D., Gambacorti‐Passerini, C., García‐Gutiérrez, V., Mauro, M. J., Leip, E., Purcell, S., Viqueira, A., Brümmendorf, T. H.

Get full text

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3 by Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez‐Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.‐S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.

Get full text

Impact of obesity on plasma natriuretic peptide levels by WANG, Thomas J, LARSON, Martin G, LEVY, Daniel, BENJAMIN, Emelia J, LEIP, Eric P, WILSON, Peter W. F, VASAN, Ramachandran S

“…The mechanisms linking obesity to hypertension have not been established, but sodium retention and excessive sympathetic tone are key contributors. The…”
Get full text

Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham heart Study by WANG, Thomas J, LARSON, Martin G, LEVY, Daniel, VASAN, Ramachandran S, LEIP, Eric P, WOLF, Philip A, D'AGOSTINO, Ralph B, MURABITO, Joanne M, KANNEL, William B, BENJAMIN, Emelia J

“…Atrial fibrillation (AF) and congestive heart failure (CHF) frequently occur together, but there is limited information regarding their temporal relations and…”
Get full text

Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease by Vasan, Ramachandran S, Larson, Martin G, Leip, Eric P, Evans, Jane C, O'Donnell, Christopher J, Kannel, William B, Levy, Daniel

“…Although frank hypertension is clearly associated with an increased risk of cardiovascular events, the implications of high-normal blood pressure are less…”
Get full text

Does the relation of blood pressure to coronary Heart disease risk change with aging? The Framingham Heart Study by FRANKLIN, Stanley S, LARSON, Martin G, KHAN, Shehzad A, WONG, Nathan D, LEIP, Eric P, KANNEL, William B, LEVY, Daniel

“…We examined the relative importance of diastolic (DBP), systolic (SBP) and pulse pressure (PP) as predictors of coronary heart disease (CHD) risk in different…”
Get full text

Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample by Fox, C.S., Larson, M.G., Hwang, S.-J., Leip, E.P., Rifai, N., Levy, D., Benjamin, E.J., Murabito, J.M., Meigs, J.B., Vasan, R.S.

“…Experimental models suggest that increased aldosterone and sodium intake are associated with renovascular damage and resultant proteinuria. We hypothesized…”
Get full text

Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic Dysfunction: The Framingham Heart Study by Vasan, Ramachandran S, Benjamin, Emelia J, Larson, Martin G, Leip, Eric P, Wang, Thomas J, Wilson, Peter W. F, Levy, Daniel

“…CONTEXT Several reports have suggested the usefulness of plasma brain natriuretic peptide (BNP) as a screening test for left ventricular hypertrophy (LVH) and…”
Get full text

Heritability and genetic linkage of plasma natriuretic peptide levels by Wang, Thomas J, Larson, Martin G, Levy, Daniel, Benjamin, Emelia J, Corey, Diane, Leip, Eric P, Vasan, Ramachandran S

“…Natriuretic peptides play a critical role in the maintenance of salt and water homeostasis and regulation of vascular tone. Thus, interindividual variation in…”
Get full text

Plasma Brain Natriuretic Peptide Levels and Blood Pressure Tracking in the Framingham Heart Study by Freitag, Michael H, Larson, Martin G, Levy, Daniel, Benjamin, Emelia J, Wang, Thomas J, Leip, Eric P, Wilson, Peter W.F, Vasan, Ramachandran S

“…ABSTRACT—Increased brain natriuretic peptide (BNP) expression in the ventricles antedates elevated blood pressure (BP) in experimental studies. We hypothesized…”
Get full text

1033PEfficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: Subgroup analysis from the BELA trial by Malhotra, H, Maru, A, Khattry, N, Ramanan, M V, Leip, E, Crescenzo, R J, Gambacorti-Passerini, C, Cortes, J E

Get full text

The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia by Brümmendorf, Tim H., Cortes, Jorge E., Busque, Lambert, Gambacorti-Passerini, Carlo, Stenke, Leif, Viqueira, Andrea, Leip, Eric, Purcell, Simon, Deininger, Michael W

“…Abstract only 7037 Background: Bosutinib (BOS) is approved for the treatment (Tx) of Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML)…”
Get full text